ArticleEJNMMI reports2026
Detection rate of PSMA PET MRI (18 F-Flotufolastat) at the onset of biochemical recurrence following radical prostatectomy.
Article in EJNMMI reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05678322 (Optimizing Timing of rhPSMA-7.3), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Optimizing Timing of rhPSMA-7.3 (18F) for Assessing Site(s) of Recurrent Disease Following Radical Prostatectomy
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
purposeThe optimal timing to obtain the initial PET-PSMA imaging study when disease recurrence is suspected following RP is controversial.
methods24 subjects with new onset of BCR following RP were enrolled. The initial PET MRI (study #1) was performed within 2 months of signing informed consent. Salvage treatment was offered only if site(s) of disease recurrence were identified by study #1. A second PSMA PET MRI (study #2) was performed 1 year following Study 1, or sooner if the 6-month PSA was > 0.5 ng/ml. PET/MR was performed in a dedicated scanner which allows simultaneous acquisition of PET and MR images following the IV administration of 8 m Ci of
resultsDisease recurrence was identified in 25% and 40% of subjects by study #1 and study #2, respectively. PSA doubling time with and without disease recurrence on study #2 was 12.8 months (IQR 4.0-17.2) and 20.8 months (20.8 months (IQR 9.1-51.7), respectively (p = 0.27). PSA prior to RP but not age, pathological grade, stage margin status or time to recurrence were significantly different between subjects with and without localization of disease recurrence.
conclusionsThe 25% disease detection and localizations justify performing PSMA PET MRI imaging at the onset of BCR. If the initial PSMA PET MRI does not identify site(s) of disease, our study supports repeating a PSMA PET study when the PSA is > 0.5 ng/ml or if the PSA doubling time is < 1 year. CLINICAL TRIAL RECORD: The study is registered on ClinicalTrials.gov with study number NCT05678322.- Registration date 12/28/2022 URL of trial registry record: https://clinicaltrials.gov/study/NCT05678322.
Indexed as
Identifiers
42850466What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.